Sarepta Therapeutics Stock Forecast, Price & News

-0.51 (-0.64 %)
(As of 06/21/2021 11:15 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume32,733 shs
Average Volume1.71 million shs
Market Capitalization$6.29 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SRPT News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Sarepta Therapeutics logo

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.73 out of 5 stars

Medical Sector

254th out of 2,100 stocks

Pharmaceutical Preparations Industry

121st out of 831 stocks

Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions

Is Sarepta Therapeutics a buy right now?

23 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last twelve months. There are currently 1 sell rating, 9 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Sarepta Therapeutics stock.
View analyst ratings for Sarepta Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Sarepta Therapeutics?

Wall Street analysts have given Sarepta Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sarepta Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Sarepta Therapeutics' next earnings date?

Sarepta Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Sarepta Therapeutics

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its quarterly earnings data on Wednesday, May, 5th. The biotechnology company reported ($2.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.01) by $0.09. The biotechnology company had revenue of $146.93 million for the quarter, compared to the consensus estimate of $140.73 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 87.11% and a negative net margin of 122.76%. During the same period last year, the firm posted ($0.23) earnings per share.
View Sarepta Therapeutics' earnings history

How has Sarepta Therapeutics' stock price been impacted by Coronavirus?

Sarepta Therapeutics' stock was trading at $102.8150 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SRPT stock has decreased by 23.7% and is now trading at $78.49.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SRPT?

23 brokers have issued 12-month price targets for Sarepta Therapeutics' shares. Their forecasts range from $73.00 to $221.00. On average, they expect Sarepta Therapeutics' stock price to reach $144.67 in the next twelve months. This suggests a possible upside of 84.3% from the stock's current price.
View analysts' price targets for Sarepta Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Sarepta Therapeutics' key executives?

Sarepta Therapeutics' management team includes the following people:
  • Mr. Douglas S. Ingram, Pres, CEO & Director (Age 58, Pay $1.29M)
  • Mr. Ian Michael Estepan, Exec. VP & CFO (Age 45, Pay $684.12k)
  • Mr. William F. Ciambrone, Exec. VP of Technical Operations (Age 57, Pay $679.94k)
  • Dr. Louise Rodino-Klapac Ph.D., Exec. VP & Chief Scientific Officer (Age 43, Pay $739.05k)
  • Dr. Gilmore O'Neill M.D., Exec. VP of R&D and Chief Medical Officer (Age 56, Pay $891.94k)
  • Mr. Joseph Bratica, Controller & VP (Age 57, Pay $438.51k)
  • Mr. Ryan E. Brown, Sr. VP, Gen. Counsel & Corp. Sec. (Age 43)
  • Dr. Diane L. Berry, Sr. VP of Global Health Policy and Gov. & Patient Affairs
  • Mr. Dallan Murray, Sr. VP & Chief Commercial Officer
  • Dr. Edward M. Kaye, Advisor (Age 72)

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?

15 employees have rated Sarepta Therapeutics CEO Douglas S. Ingram on Douglas S. Ingram has an approval rating of 95% among Sarepta Therapeutics' employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Sarepta Therapeutics' key competitors?

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and The Walt Disney (DIS).

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (7.74%), Sands Capital Management LLC (3.80%), ARK Investment Management LLC (2.33%), Ameriprise Financial Inc. (1.43%), Geode Capital Management LLC (1.22%) and Price T Rowe Associates Inc. MD (0.88%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, M Kathleen Behrens, Michael W Bonney, Richard Barry and Sandesh Mahatme.
View institutional ownership trends for Sarepta Therapeutics

Which institutional investors are selling Sarepta Therapeutics stock?

SRPT stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Ameriprise Financial Inc., Jennison Associates LLC, Waddell & Reed Financial Inc., Gilder Gagnon Howe & Co. LLC, Price T Rowe Associates Inc. MD, Alliancebernstein L.P., and Orbimed Advisors LLC. Company insiders that have sold Sarepta Therapeutics company stock in the last year include David T Howton, Hans Lennart Rudolf Wigzell, Joseph Bratica, M Kathleen Behrens, and Richard Barry.
View insider buying and selling activity for Sarepta Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Sarepta Therapeutics stock?

SRPT stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Sands Capital Management LLC, ARK Investment Management LLC, Voloridge Investment Management LLC, Tobam, Millennium Management LLC, Point72 Asset Management L.P., and Sumitomo Mitsui Trust Holdings Inc.. Company insiders that have bought Sarepta Therapeutics stock in the last two years include Douglas S Ingram, M Kathleen Behrens, Michael W Bonney, and Richard Barry.
View insider buying and selling activity for Sarepta Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $78.49.

How much money does Sarepta Therapeutics make?

Sarepta Therapeutics has a market capitalization of $6.26 billion and generates $540.10 million in revenue each year. The biotechnology company earns $-554,130,000.00 in net income (profit) each year or ($7.11) on an earnings per share basis.

How many employees does Sarepta Therapeutics have?

Sarepta Therapeutics employs 866 workers across the globe.

What is Sarepta Therapeutics' official website?

The official website for Sarepta Therapeutics is

Where are Sarepta Therapeutics' headquarters?

Sarepta Therapeutics is headquartered at 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142.

How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-274-4000 or via email at [email protected]

This page was last updated on 6/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.